Coripharma is a European pharmaceutical company, built on solid heritage. Our experienced team offers out-licensing and contract manufacturing services to pharmaceutical companies. Coripharma specializes in generic pharmaceutical products, solid oral dosage forms.

Coripharma

Coripharma is pleased to announce changes within its Commercial Operations that further strengthen the company’s Business Development organization.

Harpa Leifsdottir has been appointed Department Manager of Business Development. Harpa has been part of Coripharma for five years, most recently as Business Development Manager, and brings more than 20 years of experience from the pharmaceutical industry. In her new role, she will continue to support Coripharma’s growth strategy and will report to Lilja Valdimarsdottir, Director of Commercial Operations.

In addition, Coripharma welcomes Rhys Thomas to the Business Development team. Rhys brings extensive international experience across global and regional business development, licensing and supply agreements, strategic alliances, and M&A, with a strong track record of delivering value‑creating partnerships.

These appointments reflect Coripharma’s continued focus on strengthening its commercial capabilities and supporting long‑term growth.

Coripharma Expands and Strengthens the Business Development Team

Coripharma is pleased to announce the successful completion of a pivotal bioequivalence (BE) study for Letermovir tablets. The study demonstrated bioequivalence to the reference product, representing a key milestone in the development of this important antiviral therapy for the generic market.

The successful outcome of the pivotal BE study confirms the robustness of Coripharma’s formulation and development strategy and supports the advancement of Letermovir toward regulatory submission.

Building on its established track record in the development of complex and hard‑to‑develop generic medicines, Coripharma is evaluating strategic partnership opportunities for Letermovir tablets.

The company is open to discussions with partners who bring complementary regulatory, commercial, or market access capabilities and who share Coripharma’s focus on the disciplined, long‑term development of high‑quality generic products.

Letermovir is an antiviral agent indicated for the prophylaxis of cytomegalovirus reactivation. The availability of a generic version of Letermovir has the potential to improve patient access while supporting sustainable healthcare systems.

Coripharma Successfully Completes Pivotal Bioequivalence Study for Letermovir

Ponatinib is based on the reference product Iclusig®, used in the treatment of certain forms of leukemia. Completing this dossier showcases Coripharma’s strong technical capabilities and the effective collaboration across Coripharma’s development functions.

This milestone reflects the exceptional work and the strong cross‑functional collaboration that continues to drive Coripharma’s development pipeline forward. With the dossier now finalized, the planned submission in March 2026 positions our partners strategically for timely market access.

By advancing Ponatinib toward submission, Coripharma reinforces its commitment to expanding its oncology portfolio, supporting partners worldwide, and contributing to broader patient access to critical treatments.

Coripharma is pleased to announce the completion of its Ponatinib dossier, representing another key achievement in our ongoing commitment to advancing high‑quality generic oncology medicines.

Coripharma Finalizes Ponatinib Dossier, Targeting March 2026 Submission

Coripharma is pleased to announce the successful completion of a pivotal bioequivalence (BE) study for Binimetinib tablets. The study demonstrated bioequivalence to the reference product, representing a key milestone in the development of this important oncology therapy for the generic market.

The successful outcome of the pivotal BE study confirms the robustness of Coripharma’s formulation and development strategy and supports the advancement of Binimetinib toward regulatory submission planned for October 2026.

Coripharma is currently evaluating strategic partnership opportunities for Binimetinib tablets to join our planned submission. We welcome discussions with partners with complementary regulatory, commercial, or market access capabilities in priority territories.

Binimetinib is an orally administered MEK inhibitor. The reference product (Mektovi®) is indicated in combination with encorafenib for the treatment of melanoma.

Pivotal BE Study Completed for Binimetinib Tablets. Submission planned for October.

About us

Services

Sustainability

Careers

Pivotal BE Study Completed for Binimetinib Tablets. Submission planned for October.

More news

Coripharma Expands and Strengthens the Business Development Team

Coripharma Successfully Completes Pivotal Bioequivalence Study for Letermovir

Coripharma Finalizes Ponatinib Dossier, Targeting March 2026 Submission

+354 4206700